In conclusion, our studies suggest that co-administration of trypsin inhibitors such as ovomucoid or SBTI could enhance the therapeutic efficacy of orally delivered reparative peptides when given as single factors, such as EGF, or natural combination nutraceuticals, such as BC. The gene discussed is EGF; the disease is breast cancer.